Pseudomonas exotoxin A-like chimeric immunogens

Details Pseudomonas exotoxin A-like chimeric immunogens Pseudomonas exotoxin A-like chimeric immunogens

2008-01-01

2008-01-01

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S260100, C424S190100, C424S133100, C424S183100, C424S184100, C424S192100, C424S193100, C530S350000

Reexamination Certificate

active

09462682

ABSTRACT:
This invention providesPseudomonasexotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain ofPseudomonasexotoxin. Methods of eliciting an immune response using these immunogens also are provided.

REFERENCES:
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5190873 (1993-03-01), Lernhardt et al.
patent: 5206353 (1993-04-01), Berger et al.
patent: 5328984 (1994-07-01), Pastan et al.
patent: 5428143 (1995-06-01), Berger et al.
patent: 5458878 (1995-10-01), Pastan et al.
patent: 5512658 (1996-04-01), Pastan et al.
patent: 5573916 (1996-11-01), Cheronis et al.
patent: 5587455 (1996-12-01), Berger et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5608039 (1997-03-01), Pastan et al.
patent: 5612036 (1997-03-01), Hodges et al.
patent: 5696237 (1997-12-01), FitzGerald et al.
patent: 5705156 (1998-01-01), Pastan et al.
patent: 5705163 (1998-01-01), Pastan et al.
patent: 5821238 (1998-10-01), Pastan et al.
patent: 5843882 (1998-12-01), Boyd et al.
patent: 5854044 (1998-12-01), Pastan et al.
patent: 5863745 (1999-01-01), Fitzgerald et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5935580 (1999-08-01), Ladant et al.
patent: 5965406 (1999-10-01), Murphy
patent: 5980895 (1999-11-01), Pastan et al.
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 5990296 (1999-11-01), Pastan et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6020145 (2000-02-01), Hellstrom et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6051405 (2000-04-01), FitzGerald et al.
patent: 6074644 (2000-06-01), Pastan et al.
patent: 6083502 (2000-07-01), Pastan et al.
patent: 6086900 (2000-07-01), Draper
patent: 6090388 (2000-07-01), Wang
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6146631 (2000-11-01), Better et al.
patent: 6303120 (2001-10-01), Danishefsky et al.
patent: 6423513 (2002-07-01), Fitzgerald
patent: 6426075 (2002-07-01), Fitzgerald
patent: 6498233 (2002-12-01), Wels et al.
patent: 6531133 (2003-03-01), Lorberboum-Galski et al.
patent: 6783761 (2004-08-01), Grimes et al.
patent: 6881718 (2005-04-01), FitzGerald et al.
patent: 2002/0106370 (2002-08-01), Cardy et al.
patent: 2004/0247617 (2004-12-01), Liao et al.
patent: 2005/0079171 (2005-04-01), FitzGerald et al.
patent: 0583794 (1987-09-01), None
patent: 0 439 954 (1990-12-01), None
patent: 439954 (1991-08-01), None
patent: 95/31483 (1995-11-01), None
patent: WO 95/31483 (1995-11-01), None
patent: WO 97/13529 (1997-04-01), None
patent: WO 98/20135 (1998-05-01), None
Ashorn, Per et al, Proc. Nat'l Acad. Sci, (USA), vol. 87, p. 8889-8893, Nov. 1990.
Chaudhary, VK et al, Nature, vol. 335, Sep. 22, 1988, pp. 369-372.
Cryz et al (1995)Vaccine, vol. 13, pp. 67-71.
Moore, Chapter 2, p. 63-67, Synthetic Peptides Alesers Guide, WH Freeman & Co, N.Y.
Swiss Prot Accession No. P11439,Pseudomonas aerginosaexotoxin A amino acid sequence entered in Oct. 1989.
Cryz et al, 1995, Vaccine, vol. 13(1), pp. 67-71, Human immunodeficiency virus-1 principle neutralizing domain peptide-toxin A conjugate vaccine.
Catasti, P et al, The Journal of Biological Chemistry, vol. 270(5), Feb. 3, 1995, 2224-2232, Local and Global Structural Properties of the HIV-MN V3 Loop.
Donnelly, John J et al, PNAS, 1993, vol. 90, pp. 3530-3534, Apr. 1993.
Brinkmann and Pastan, “Immunotoxins against cancer,”Biochimica et Biophysica Acta, 1198:27-45 (1994).
Chaudhary, V.K. et al., “Pseudomonasexotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity,”Proc. Natl. Acad. Sci. USA, 87:308-312 (1990).
Cryz, Jr., S.J. et al., “Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine,”Vaccine, 13:67-71 (1995).
Cryz, Jr., S.J. et al., “Safety and Immunogenicity of aPseudomonas aeruginosaO-Polysaccharide Toxin A Conjugate Vaccine in Humans,”J. Clin. Invest., 80:51-56 (1987).
Cryz, Jr., S.J. et al., “Safety and Immunogenicity ofEscherichia coliO18 O-Specific Polysaccharide (O-PS)-Toxin and O-PS-Cholera Toxin Conjugate Vaccines in Humans,”J. Infectious Disease, 163:1040-1045 (1990).
FitzGerald, D.J. et al., “Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras,”J. of Biol. Chem., 273(16):9951-9958 (1998).
Lukac, M. et al., “Toxoid ofPseudomonas aeruginosaExotoxin A Generated by Deletion of an Active-Site Residue,”Infection and Immunity, 56(12):3095-3098 (1988).
Que, J.U. et al., “Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines againstPlasmodium falciparumCircumsporozoites,”Infection and Immunity, 56:2645-2649 (1988).
Reiter et al., “Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv -fragments,”Nature Biotechnology, 14:1239-1245 (1996).
Backstrom, M. et al., “Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit,”Gene, 149:211-217 (1994).
Berman, P.W. et al., “Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160,”Nature, 345:622-625 (1990).
Eaton, A.M. et al., “An Anti-gp41 Human Monoclonal Antibody That Enhances HIV-1 Infection in the Absence of Complement,”Aids Res. Hum. Retroviruses, 10:13-18(1994).
Emini, E.A. et al., “Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody,”Nature, 355:728-730 (1992).
Evans, D.J. et al., “An engineered poliovirus chimaera broadly reactive HIV-1 neutralizing anitboies,”Nature, 339:385-388 (1989).
Fontenot, J.D. et al., “Human immunodeficiency virus (HIV) antigens: Structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins,”Proc. Natl. Acad. Sci. USA, 92:315-319.
Javaherian, K. et al., “Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein,”Proc. Natl. Acad. Sci. USA, 86:6768-6772 (1989).
Kovacs, J.A. et al., “Induction of Humoral and Cell-mediated Anti-Human Immunodefieiency Virus (HIV Responses in HIV Sero-negative Volunteers by Immunization with Recombinant gp160,”J. Clin. Invest., 92:919-928 (1993).
Mitchell, W.M. et al., “Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques,”Aids, 9:27-34 (1995).
Montefiori, D.C. et al., “Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors,”J. Infect. Dis., 173:60-67.
Rusche, J.R. et al., “Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120,”Proc. Natl. Acad. Sci. USA, 85:3198-3202 (1988).
Steimer, K.S. et al., “Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120,”Science, 254:105-108 (1991).
Toth, F.D. et al., “Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro,”Clin. Exp. Immunol., 96:389-394.
Wang, C.Y. et al., “Long-Term High-Titer Neutralizing Activity Induced by Octameric Synthetic HIV-1 Antigen,”Science, 254:285-288 (1991).
White-Scharf, M.E. et al., “Broadly Neutralizing Monoclonal Antibodies to the V3 Region of HIV-1 Can Be Elicited Peptide Immunization,”Virology, 192:197-206 (1993).
U.S. Appl. No. 09/462,713, Fitzgerald.
Choe, et al. Cancer Res “B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form ofPseudomonasexotoxin is fused to the Fab fragment of monocional antibody B3” Jul. 1994 vol. 54, Issue 13 pp. 3460-3467.
Kreitman, et al. Bioconjug Chem “Properties of Chimeric Toxins with Two Recognition Domains: Interleukin 6 and tran

Affiliated with

Also associated with

Rating

Pseudomonas exotoxin A-like chimeric immunogens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pseudomonas exotoxin A-like chimeric immunogens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pseudomonas exotoxin A-like chimeric immunogens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3934401